OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
SPHRY
Starpharma Holdings Ltd.
4-6 Southampton Crescent
Abbotsford, VA 3067
Australia
4-6 Southampton Crescent
Abbotsford, VIC 3067
Australia
None
Level 19 Freshwater Place
2 Southbank Boulevard
Southbank, VA 3006
Australia
Level 31
152-158 St Georges Terrace
Perth, WA 6000
Australia
Level 10, 20 Martin Place
Sydney, NSW 2000
Australia
Starpharma has developed an innovative drug delivery platform using proprietary dendrimer nanoparticles, known as DEP®, to enhance the efficacy and tolerability of pharmaceutical products. Starpharma utilizes the DEP® technology for its own pipeline of assets and collaborates with partners to apply this technology to their drug discovery programs and pipeline assets. Starpharma’s portfolio of dendrimer-based products includes clinical-stage oncology assets, preclinical radiopharmaceuticals and antibody-drug conjugate (ADC) assets, research collaborations, and commercially marketed over-the-counter (OTC) products.
Starpharma's HQ & facilities are located in Melbourne Australia.
